ASC Therapeutics news
ASC Therapeutics has joined forces with Charles River to scale the manufacturing of ASC618, its second-generation virus-based gene therapy for hemophilia A.
The agreement expands upon their current collaboration, begun in 2019 that focused on a
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A.
Hemophilia A is caused by the lack of the blood clotting factor VIII (FVIII), a protein whose instructions are provided by F
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies
- First known bovine model used to demonstrate safety and efficacy in gene replacement therapy
- MSUD is a severe genetic disease with liver transplantation or dietary restriction as the only treatments currently available
ASC Therapeutics in partnership with the UMass Chan Medical School and the Clinic for Special Children (CSC), presented safety and efficacy results of a dual-function gene replacement vector therapy in murine and bovine models of cl
- Podium presentation highlights significant transduction and transgene expression in pharmacokinetic studies in mice, non-human primates and a humanized liver model
- Poster presentation focuses on pharmacology, toxicology and safety studies
- Poster presentation focuses on the development of a novel transduction assay to evaluate in-vitro relative Infectivity
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of trans
The U.S. Food and Drug Administration (FDA) has given fast track designation to ASC618, an investigational one-time gene therapy for hemophilia A in the pipeline of ASC Therapeutics.
Fast track status works to speed the development and regulatory revie
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic, and other rare diseases has received from the United States (U.S.) Food and Drug Administration (FDA) the Fast Track Designation for ASC618, a second-generation gene therapy of hemophilia A. In addition, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) h